Literature DB >> 9242797

30 years of penicillin-resistant S pneumoniae: myth or reality?

F W Goldstein1, J Garau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9242797     DOI： 10.1016/s0140-6736(05)62222-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

Review 1.  A unified anti-mutant dosing strategy.

Authors:  Xilin Zhao; Karl Drlica
Journal:  J Antimicrob Chemother       Date:  2008-06-10       Impact factor: 5.790

2.  The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance.

Authors:  D J Austin; K G Kristinsson; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-02       Impact factor: 11.205

3.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

4.  PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model.

Authors:  Bruce A Green; Ying Zhang; Amy W Masi; Vicki Barniak; Michael Wetherell; Robert P Smith; Molakala S Reddy; Duzhang Zhu
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.

Authors:  Dennis O Gor; Xuedong Ding; David E Briles; Michael R Jacobs; Neil S Greenspan
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

6.  Recombinant PhpA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge.

Authors:  Y Zhang; A W Masi; V Barniak; K Mountzouros; M K Hostetter; B A Green
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  In vitro and in vivo antibacterial activities of OPC-20011, a novel parenteral broad-spectrum 2-oxaisocephem antibiotic.

Authors:  M Matsumoto; H Tamaoka; H Ishikawa; M Kikuchi
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

8.  Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice.

Authors:  Dennis O Gor; Xuedong Ding; Qing Li; John R Schreiber; Michael Dubinsky; Neil S Greenspan
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.